

**Listing of the Claims:**

This listing of claims will replace all prior version, and listings, of claims in the application:

1. (Currently amended) A method of treating a patient with chronic lymphocytic leukemia (CLL), comprising:
  - (a) selecting[[::]] a patient having symptoms of chronic lymphocytic leukemia, and
  - (b) administering to said patient a therapeutically effective dose of a pharmaceutical agent formulation comprising an inhibitor that specifically inhibits enzyme activity of Type 4 cyclic adenosine monophosphate phosphodiesterases to said patient under conditions such that said symptoms are reduced.
2. (Original) The method of Claim 1, wherein said administering is enteral administration.
3. (Original) The method of Claim 2, wherein said enteral administration is oral administration.
4. (Original) The method of Claim 1, wherein said administering is parenteral administration.
5. (Original) The method of Claim 1, wherein said patient is a naïve patient.
6. (Original) The method of Claim 1, wherein said patient is immunocompromised.
7. (Original) The method of Claim 1, wherein said patient is unresponsive to chemotherapy with alkylating agents.
- 8-14. (Cancelled)
15. (Currently amended) A method, comprising:
  - (a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and (ii) a formulation comprising an inhibitor that specifically inhibits

Type 4 cyclic adenosine monophosphate phosphodiesterases, wherein said inhibitor is (4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone); and

(b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.

16. (Previously presented) The method of claim 1, wherein the inhibitor is used in combination with a cytotoxic drug to augment apoptosis in chronic lymphocytic leukemia cells.